Results 41 to 50 of about 11,301 (165)

Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study

BMC Medicine, 2023
Background With increasing hypercholesterolemia prevalence in East Asian adolescents, pharmacologic interventions (e.g., HMGCR inhibitors (statins) and PCSK9 inhibitors) may have to be considered although their longer-term safety in the general ...
Shan Luo, Hugh Simon Lam, Yap Hang Chan, Clara Sze Man Tang, Baoting He, Man Ki Kwok, Gabriel M. Leung, C Mary Schooling, Shiu Lun Au Yeung   +8 more
doaj   +1 more source

PCSK9 inhibitors for LDL lowering [PDF]

Trends in Cardiovascular Medicine, 2015
In 2003, families were described with a rare, autosomal dominant form of familial hypercholesterolemia due to gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) [1]. Subsequent studies demonstrated that PCSK9 is secreted from liver and accelerates degradation of LDL receptors [2,3].
openaire   +2 more sources

Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects

Cancer Nexus, EarlyView.
ABSTRACT Lipid nanoparticles (LNPs) represent the most clinically advanced platform for RNA delivery and have enabled major breakthroughs in vaccines and gene therapies. However, their broader application is still limited by inefficient extrahepatic delivery, immunogenicity, and insufficient control over tissue‐ and cell‐specific targeting. This review
Yu Han, Ying Wang, Xintao Gao, Yan Lei, Yantao Li, Zhiyong Tang   +5 more
wiley   +1 more source

Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study

BMC Cancer
Background The causal impact of lipid-lowering drugs on ovarian cancer (OC) and cervical cancer (CC) has received considerable attention, but its causal relationship is still a subject of debate.
Jinshuai Li, Zixian Yang, Tao Wang, Mengqi Li, Xiangjian Wu, Xiaoyan Fu, Chunfeng Yang, Yangpu Li, Ximing Wang, Zhiming Lan, Minfang Li, Sheng Chen   +11 more
doaj   +1 more source

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis

Frontiers in Cardiovascular Medicine
BackgroundIn recent years, the position of PCSK9 inhibitors as adjuvant therapy to statins in guidelines has further improved. However, there remained a dearth of direct comparative studies among different PCSK9 inhibitors. Therefore, this study aimed to
Dong Liu, Jin Zhang, Xiaoyu Zhang, Fengli Jiang, Yiping Wu, Beibei Yang, Xinghuan Li, Xiongxiong Fan, Han Li, Yu Sun, Ruijie Gou, Xinyu Wang   +11 more
doaj   +1 more source

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro

Molecules, 2018
The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia.
Li Li, Chen Shen, Ya-Xuan Huang, Ya-Nan Li, Xiu-Feng Liu, Xu-Ming Liu, Ji-Hua Liu   +6 more
doaj   +1 more source

PCSK9 inhibitors – past, present and future [PDF]

Expert Opinion on Drug Metabolism & Toxicology, 2015
Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are the treatment of choice for lowering LDL-C but a considerable number of patients treated with statins are unable to achieve LDL-C target values and many are statin-intolerant.
openaire   +2 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

Tzu Chi Medical Journal
A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases.
Je-Wen Liou, Pei-Yi Chen, Wan-Yun Gao, Jui-Hung Yen   +3 more
doaj   +1 more source

Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review

Therapeutic Advances in Drug Safety, 2021
Neurocognitive adverse events have been observed with the widespread use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or “statins,” which reduce low-density lipoprotein cholesterol (LDL-C) levels and subsequently cardiovascular risk. The United
Wei C. Yuet, Didi Ebert, Michael Jann
doaj   +1 more source